Daiichi Sankyo Company, Limited Share Price Other OTC
Equities
DSNKY
US23381D1028
Pharmaceuticals
Sales 2024 | 1,602B 10.28B 821B | Sales 2025 * | 1,767B 11.34B 906B | Capitalization | 10,323B 66.25B 5,292B |
---|---|---|---|---|---|
Net income 2024 | 201B 1.29B 103B | Net income 2025 * | 191B 1.22B 97.8B | EV / Sales 2024 | 5.72 x |
Net cash position 2024 * | 556B 3.57B 285B | Net cash position 2025 * | 629B 4.04B 323B | EV / Sales 2025 * | 5.49 x |
P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
52.1
x | Employees | - |
Yield 2024 |
1.05% | Yield 2025 * |
1.09% | Free-Float | 97.04% |
Latest transcript on Daiichi Sankyo Company, Limited
Managers | Title | Age | Since |
---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 31/03/07 |
Hiroyuki Okuzawa
PSD | President | 61 | 31/03/17 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 31/05/19 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 31/05/19 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 31/03/07 |
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |